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standardized the oncology treatment fields available in the specific oncology data-
base (DataSUS AQ). Standardization included harmonization of different names 
used for the same drug name (i.e., cetuximab, cetux, cetukimabe and ketuxim), 
including generic and brand names. We also converted acronyms use in NCCN 
and MOC Brazil guidelines to the generic name (i.e.: fluoracil and 5FU; irinotecan 
and CPT-11). We created a new standardized table with additional fields (regimen 
name, drugs used, adjuvant therapy and a high/low cost flag). For this analysis we 
filtered by APAC (High complexity procedures approval) code for colorectal cancer 
(CRC) and lung cancer (LC) from 2012 to 2014. All blank or not identified regimens 
were excluded from this analysis. The final sample was composed by 50,729 CRC 
and 23,525 LC records. Results: It was compared the total number of regimens 
available at raw data and those standardized. Regarding CRC regimens we found 
7,698 different treatments in the raw database and 82 in the standardized dataset, 
a considerable reduction. In raw data, the most frequent regimen was FOLFOX rep-
resenting 7.9% of all records, in contrast to standardized dataset where FOLFOX 
regimen represented 33.6% of all records. We found 262 records written in differ-
ent ways in the raw database that referred to FOLFOX. Analyzing LC records, the 
most frequent regimen in raw data was carboplatin+taxo representing 3.1% of LC 
APACs claims in comparison to the standardized dataset where carboplatin+taxol 
represented 27.6% of all claims; 278 raw records had different names referring to 
carboplatin+taxol. ConClusions: DataSUS can be a reliable source on oncology 
consumption therapies after standardizing data fields that were originally intro-
duced by manual typing.
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ExtRacting and Using data FRoM ElEctRonic MEdical REcoRds (EMR) 
to MonitoR QUality oF caRE and PREscRiPtion PattERns FoR diabEtEs 
PREvEntion and contRol in oUtPatiEnt clinics oF low and Mid 
REsoURcEs coUntRiEs: thE casE oF coliMa, MExico
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objeCtives: Evaluate the possibility of extracting data from the EMR used by 
the Health Services of Colima, Mexico and use it to assess the quality of care 
and prescription patterns for Diabetes prevention and control in outpatient clin-
ics. Methods: A copy of the entire EMR database, including personal identifica-
tion variables, was obtained from the Health Services of Colima. A data verification 
and validation process was carried out including checking for EMR duplicity using 
Structured Query Language (SQL) and phonetic algorithms. A flat table for each 
patient’s encounter with the health services was constructed in order to have a 
longitudinal record along with vital signs, diagnostic and control tests as well as 
drugs prescribed. Each encounter was then coded to reflect in a single character 
string the main variables of diabetes care: number of visit after diagnosis, glucose 
measurement, drugs administered, as well as eye and feet examination. Results: 
The EMR in Colima initiated its operation in 2005 as a pilot in 3 clinics, in 2010 it 
covered about 50% of the state’s clinics (55) and in 2013 reached 100%: 117 clin-
ics. A total of 393,398 records were extracted and consolidated with 2,271,251 
outpatient visits in the period 2005 – march 2014. The age and sex structure of 
the population in the EMR was very similar to that of the 2010 population center 
for the state. Eleven percent of the population eighteen or older in the database 
was diagnosed with diabetes; only 45% of these had at least one glucose exam 
and only 16% were taking insulin. The most frequent medication prescribed was 
metformine. ConClusions: The use of data from EMR is suitable to evaluate 
quality of care and prescription patterns in the prevention and control of diabetes 
mellitus. Continuing monitoring established quality parameters and prescription 
may help to improve quality.
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coMPaRison oF social EQ-5d tiME tRadE-oFF valUEs in chilE 2008-2013: 
do gEogRaPhical diFFEREncEs REally MattER?
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objeCtives: To evaluate differences in social values collected in the Chilean 
EQ-5D valuations surveys of 2008 and 2013 using the time trade-off method 
(TTO). Methods: Responses from a total of 3701 individuals who participated in 
the 2008 and 2013 Chilean EQ-5D valuation surveys were analyzed to assess dif-
ferences in TTO values from 31 health states between both studies adjusting for 
gender, age and educational attendance. Differences were explored using several 
ordinary least square (OLS) regression models taking into account sampling weights. 
Variations of TTO values between the Metropolitan Region (MR) and the rest of the 
country were evaluated using data only from the 2013 survey adjusting not only 
for socio-demographic characteristics, but also for other variables known to have 
an effect on respondent´s values such as self-reported health status, marital status 
and level of difficulty answering the TTO questionnaire. Results: A basic regres-
sion model showed significant differences (p value < 0.001) between both surveys 
indicating that 2008´s TTO values collected only in the MR were lower than 2013´s 
TTO values collected alongside the whole country. These differences remain after 
adjusting for confounding variables. Exploring possible determinants of geographi-
cal differences at individual level based on 2013 data, only years of education and 
a high level of difficulty answering the TTO questionnaire appeared to have a sig-
nificant effect on valuations (p value < 0.001). However, those effects were marginal 
and do not fully explain the differences found between TTO values collected in the 
MR and the rest of the country. ConClusions: Our findings support the idea that 
cultural/geographical differences could have a significant impact on social values 
within-country. These differences constitute an important factor that should be 
taken into consideration when designing and analyzing results from these types 
of studies on a national level. Further international research is required to improve 
knowledge on this topic.
broadly similar to the Uruguayan population. Forty four percent of the subjects 
reported no problems on any of the five EQ-5D-5L dimensions. Older respondents 
reported more problems in all dimensions. Mean self-reported VAS was 79.63 
(SE 0.58); it decreased with age and was lower in women. As OLS model showed 
logical inconsistencies, robust modelling was chosen to derive social values. 
Values ranged from -0.264 to 1. States with a misery index= 6 had a mean value 
of 0.965. When comparing the prediction for a misery index= 6 in the Uruguayan 
population with the Argentinian EQ-5D-5L crosswalk value set, the Uruguay val-
ues are about 0.05 higher. The mean index value for the general population in 
Uruguay, using the final main effects Uruguayan EQ-5D-5L value set, is 0.895. In 
general, older people had worse values and males had slightly better values than 
females. ConClusions: We derived the EQ-5D-5L Uruguayan value set, the first 
in Latin America. These results will help inform decision-making using economic 
evaluations for resource allocation decisions.
PP3
cost-EFFEctivEnEss analysis FoR cERvical cancER scREEning Using 
hPv tEsts in bRazil
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objeCtives: The aim of this study is to estimate the cost-effectiveness of cervical 
cancer primary screening with HPV PCR tests in Brazil. Methods: A Markov model 
captured the outcomes of 1,000 non-hysterectomized women ages 25 years and 
older who transitioned annually across possible health states and were screened 
over a 45-year period in Brazil. This model was used to compare three strategies: 
(1) cytology alone (2) Pooled HPV with reflex cytology (3) HPV with 16/18 genotyping 
and reflex cytology, from a payer’s perspective. The one-way and probabilistic sen-
sitivity analyses were performed. Additionally, the screening and cancer treatment 
costs were calculated according to DATASUS 2012 (Departamento de Informática do 
Sistema Único de Saúde - Brazil) public data, in Brazilian Real (BRL) and discounted 
at an annual rate of 5%. Results: The primary screening with the strategy (3) HPV 
with 16/18 genotyping and reflex cytology, results in earlier detection of clinically 
relevant high-grade CIN (Cervical Intraepithelial Neoplasia) at the initial visit along 
with efficient use of healthcare resource in Brazil. In addition, the model suggested 
an Incremental Cost Utility Ratio (ICUR) and Incremental Cost Effectiveness Ratio 
(ICER) of 13,266 R$/QALY and 51,389 R$/LYG, respectively, comparing the strategies 
(3) to (1), whereas, the strategy (2) was dominated by strategy (3). ConClusions: 
The current analysis indicated that the HPV with 16/18 genotyping test (strategy 3) 
is cost-effective for primary cervical cancer screening in women aged ≥ 25 years in 
Brazil due to the ICER ≤ 3 Brazilian GDP per capita, according to the World Health 
Organization’s recommendations.
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an UndEvEloPEd PictURE: thE availability oF Utility valUations in 
latin aMERica – how will thEy aFFEct Qalys?
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objeCtives: Health Technology Appraisal processes in Latin American countries 
are of increasing importance. For decisions made on the basis of cost per qual-
ity-adjusted life year, the utility inputs used in the economic model are typically 
influential on the outcome. Utility valuations vary from country to country and we 
therefore sought to review the availability of valuations for Latin American coun-
tries. Methods: Using PubMed, a structured search was conducted to identify 
which of the common generic, preference-based instruments had valuations for 
Latin American countries. The instruments included in the search were EQ-5D, 
SF-6D and HUI. Identified studies were retrieved in full text and, where extant, 
valuations of each instrument across different countries were compared. Results: 
The review identified no HUI valuations, one SF-6D valuation (in Brazil) and three 
EQ-5D valuations (in Argentina, Chile and Brazil). The three EQ-5D valuations all 
used time trade-off methodology but the sampled states used differed such that 
only 13 states had an observed value across all three studies. Visual comparison 
of these observed states revealed considerable divergence of the Chilean valuation 
from the Brazilian and Argentinian valuations in the lower health states. This trend 
remained when the final modelled values for the full set of EQ-5D health states were 
plotted. Divergence increased in worse states, producing greater utility differences 
between states in Chile. ConClusions: There are currently a limited number of 
valuation sets available in Latin America. Only EQ-5D has multiple valuations to 
allow inter-country comparison, revealing clear differences. Such noticeable varia-
tions between countries in the value of changing health states make it unlikely that 
cost-utility analyses are generalisable in the region, affecting pricing and reimburse-
ment decisions. Further work therefore remains to generate valuation sets for other 
countries in Latin America to allow an understanding of how reimbursement may 
be affected by increasing use of HTA.
REsEaRch on MEthods stUdiEs
RM1
standaRdization PRocEss oF Raw datasUs and consUMPtion 
analysis oF oncology thERaPiEs in thE bRazil PUblic hEalth caRE 
systEM: a coMPaRison bEtwEEn Raw and standaRdizEd datasEt in 
coloREctal and lUng cancER
Fabre Ballalai Ferraz A1, Rosim R1, Anaya P2
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objeCtives: To compare results of oncology drugs consumption extracted from 
DataSUS raw database with those obtained after standardizing and cleaning data-
base fields. Methods: We used the SUS database available from DataSUS FTP and 
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Early elimination harmful substances ( smoking cessation), new medications for 
moderate stage of COPD, are warranted to reduce the severity and frequency of 
exacerbations and the related cost impact of the disease.
PRM3
RivaRoxavan+EnoxiPaRina coMPaRado a EnoxiPaRina En PaciEntEs 
PostoPERadoR dE REMPlazo aRticUlaR dE Rodilla y cadERa
vazquez Alonso Mf
IMSS UMAE LOMAS VERDES, NAUCALPAN EDO DE MEXICO, Mexico
objeCtivos: Evaluar el efecto d rivaroxaban + enoxiparina comparado a 
enoxparina en pacientes postoperados de reemplazo articuñar de cadera y 
rodilla. MetodologíAs: se realizo en el servicio de cirugia de reemplazos articu-
lares de la UMAE LOMS VERDES DEL IMSS en el periodo de enero a noviembre 2014, 
estudio casos y controles longitudinal y prospectivo. se estudiaron 85 paciente de 
ambos sexos, en edades mayores de 18 años con diagnostico de coxartosis, gonar-
trosis sometidos a cirugia de reem´plazo articular de rodilla y cadera manejados 
con rivaroxaban y enoxiparna y enoxiparina. ResultAdos: Gpo A amenjados con 
enoxiparina 41 paciente 25 masculino y 16 femenino 21 con artoplastia total de 
cadera y 20 de rodilla, co promedio de edad 63a. 2 con obesidad con imc mayor a 
27, con valoracion predictivo de wells 6 paciente con alto, valorados con escala de 
wells a los 15 dias de 6 alta, 35 moderada y cero baja, no torbos por doppler.este 
gpo, manejado con enoxiparina y rivaroxaban. grupo B, 55 pacientes 25 masculino 
y 30 femeninos con 31 pacientes con artroplastia total de cadera y 24 artroplastia 
total de rodilla, con un promedio de edad 66, 1 paciente con lesion tumoral. alos 
15 dias presentaro 9 pacients conprobabilidad altas y moderados cero bajo. la sin-
tomatologia presente es el dolor, trombosis diagnosticado clinica por doppler y 
una muerte pacientes manejado con enoxiparina y rivaroxaban. ConClusiones: 
La Trombosis Venosa Profunda, Es Una Complicaciones Postoperatproa Frecuente 
Y Grave En Los Pacientes Postoperados De Artroplastia Total De Rodilla Y Cadera, 
Los Pacientes Presentaron En Fases Iniciales Datos Clinicps De Trombosis Venosa 
Profunda Con Indice De Wells A Revisando Estos Datos Podemos Decir Que Apesar 
De La Admnistracion De Rivaroxaban El Riesgo De Presentar Un Evento Trombotico 
Es Inminente En Todos Los Paciente Postopeprados De Artroplastia Total De Rodilla 
Y Cadera.
REsEaRch on MEthods – cost Methods
PRM4
cost-bEnEFit analysis oF wholE body bonE scintilogRaPhy in thE PRE-
tRasnPlant assEsMEnt oF adUlt PatiEnts bEaREs oF hEPatocEllUlaR 
caRcinoMa in a livER tRanaPlant list in thE soUth oF bRazil
Balbinotto G1, Rodriguez S2, BrandÃo A2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2UFCSPA, PORTO ALEGRE, Brazil
bACkgRound: In patients with hepatocellular carcinoma (HCC), bone metastasis 
occurs rarely in the natural disease course. Current pre-transplantation evaluation 
policy includes mandatory bone scintigraphy as a requisite for selecting patients 
to be included on hepatic transplantation list. Previous studies, however, have 
shown that routine scintigraphy is not cost-effective and generates unnecessary 
Health System costs. objeCtives: Evaluate for the first time in Brazil the perti-
nence of systematically requesting whole-body bone scintigraphy in early-stage 
HCC adult patients as a requisite for inclusion on the waiting list for HTx from a 
deceased donor, according to a reference center in South Brazil. Methods: We 
retrospectively analyzed 256 medical files of early-stage HCC patients who under-
went hepatic transplantation, 187 of whom were subjected to pre-transplantation 
bone scintigraphy. Results: The most common etiology was hepatitis C viral 
infection, the most common liver functional class was Child B, and 78% of the 
patients met the Milan criteria. None of the 187 scintigraphies was positive for 
metastasis. The 1- and 5-year post-hepatic transplantation survival rates among 
patients subjected to bone scintigraphy were 81% and 69%, respectively; those 
among patients not subjected to scintigraphy were 78% and 62%, respectively (p 
= 0.25). The 1- and 5-year post-HTx recurrence rates among patients subjected 
to bone scintigraphy were 4.8% and 10.7%; those among patients not subjected 
to scintigraphy were 2.9% and 10.1%, respectively (p = 0.46). ConClusions: The 
cost generated by the current evaluation policies, US$ 27.582, did not result in the 
detection of any sub-clinical metastasis and therefore failed to provide positive 
cost-effectiveness.
PRM5
ExPloRing vaRiation in cost-EFFEctivEnEss EstiMatEs in stUdiEs that 
EvalUatE adUlt PnEUMococcal vaccination in latin aMERica
Constenla DO1, Garcia C1, Silver D1, Qi A1, Yang HK2
1Johns Hopkins University, Baltimore, MD, USA, 2Merck & Co., Inc., West Point, PA, USA
objeCtives: To assess the wide variation in cost-effectiveness estimates in stud-
ies that evaluate the economics of pneumococcal vaccines currently approved 
for adults in Latin America. Methods: To explain this variation we reviewed the 
relevant peer- and non-peer reviewed literature of Pneumovax23 and Prevnar13 
in the Latin American context. We systematically searched 6 databases to iden-
tify studies published between 2000 and 2014 presenting economic impact data of 
these two vaccines among adults in the region. Studies containing abstracts and 
emerging work pending publication were considered given limited range of pub-
lished studies. Selected studies were reviewed in terms of country of evaluation, 
strategies assessed, study design, method of evaluation, cost measures, perspec-
tive, and period of analysis. We used the values of model parameters derived from 
these papers and applied standard formula to estimate potential DALYs avoided 
or QALYs gained. To capture the strengths of the economic evidence, we classified 
the kinds of data used in the papers as ‘primary,’ ‘secondary’ or ‘both’, and critically 
appraised the papers using a preset quality checklist. Results: A total of 30 peer- 
and non-peer reviewed papers presenting economic data were identified. Several 
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ModElo dE caRactERización dE Una Población aFiliada a Una 
asEgURada En coloMbia, MEdiantE Una MEtodología dE agRUPación 
PoR RiEsgo
Romero M1, Marrugo Figueroa RD2, Benavides M3, Alzate P3, Reinales J4, Quinche G4, 
Barrios E4
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objeCtives: caracterizar la situación de salud y su relación con el costo de aten-
ción mediante un modelo de agrupación de pacientes, por el riesgo de presentar 
enfermedades agudas, crónicas instauradas y multienfermedad. Methods: a partir 
de la información de uso de servicios reportados y consolidados en el año 2013, se 
realizó una clasificación de pacientes bajo tres categorías: pacientes sin contacto 
o con enfermedades agudas, con enfermedad crónica instaurada y con múltiples 
enfermedades crónicas. Los pacientes identificados como crónicos cumplían las sigu-
ientes características: con diagnósticos según el código CIE-10 y con un mínimo de 
tres atenciones. Se identificaron los costos de atención de cada grupo de pacientes en 
cinco categorías: hospitalaria, urgencias, domiciliaria, medicamentos y ambulatoria. 
Cabe destacar que solo se incluyeron los costos que están dentro del plan de benefi-
cios. Results: de los 3.008.216 de pacientes analizados, el 7,99% padece por lo menos 
una enfermedad crónica y tiene una participación del 37,2% del costo total, mientras 
que el 0,59% padece dos o más enfermedades crónicas y representa el 5,53% del costo 
total. Se destaca que el 4,87% de la población padece enfermedades cardiovasculares-
diabetes y representan el 18,06%, el 19,46% y el 20,42% del costo total, costo por medi-
camento y costo hospitalario respectivamente. Asimismo, los pacientes con cáncer, 
representan el 0,25% de la población afiliada y tienen un impacto en costo del 5,4% 
sobre el costo total, constituido principalmente por cáncer de mama. Para el análisis 
los no crónicos fueron agrupados por ciclo vital y sexo. ConClusions: el costo pro-
medio anual por paciente asciende a $595.992 pesos, no obstante, la identificación 
de grupos de riesgo, como los de enfermedades crónicas instauradas, brindan una 
mejor perspectiva de la distribución del gasto en salud y muestra el comportamiento 
invertido entre costo y cantidad de pacientes referido por el modelo de Kaiser.
REsEaRch on MEthods – clinical outcomes Methods
PRM1
EsPEsoR coRnEal cEntRal En PERsonas sanas En chilE y coRRElación 
EntRE distintos Métodos dE MEdición
Fau C, Nabzo S, Saez C, Zuñiga C
Fundacion 2020, Santiago, Chile
La medición de la Paquimetria Central (PC) en los últimos años ha tenido cada vez 
más valor en diferentes situaciones medicas tanto diagnosticas como terapéuticas. 
Diversos estudios han demostrado la influencia de la raza en esta medición, siendo 
en afroamericanos y japoneses significativamente menor.objeCtivos: medir la PC 
en una población de personas sanas en Chile, evaluar su relación con la edad y sexo, 
y comparar los métodos de medición más frecuentes en términos de precisión y 
correlación con la Paquimetría Ultrasónica (PCUS). MetodologíAs: Se diseño un 
estudio prospectivo observacional en 125 pacientes sanos mayores de 20 años. Las 
mediciones de la PC fueron realizadas con los equipos Pentacam, Pachmate DgH y 
RTVue OCT. ResultAdos: La PC-US fue de 539μ ± 35,5μ , no se encontró correlación 
significativa con la edad (p= 0,4 y r= 0,07) así como tampoco con el sexo (p= 0,73). 
La PC medida con Pentacam fue 534,79μ ± 34,9μ , su correlación con la PC-US fue 
r= 0,96, su diferencia fue de 5,93μ ± 10,5μ (p< 0,001), la PC del OCT RTVue fue de 
535,5μ ± 36,24μ , su correlación con la PC-US fue r= 0,98 y su diferencia 7,19μ ± 7,2μ 
(p< 0,001). ConClusiones: La PC-US fue significativamente más delgada que la 
reportada en poblaciones caucásicas, hispanas o española, esta fue similar a la 
reportada en estudios realizados en población japonesa. El OCT RTVue obtuvo una 
correlación mayor con límites de concordancia más estrechos que el Pentacam en 
relación a la PC-US.
PRM2
what doEs coPd ExacERbation MEans FoR PatiEnts and FoR 
hEalthcaRE?
Capova G
Charles University, Praha/Prague, Czech Republic
WHAT DOES COPD EXACERBATION MEANS FOR PATIENTS AND FOR HEALTHCARE? 
Capova G1,Kristova V2 12nd Faculty of Medicine Charles University Prague, Dep of 
Pneumology, Czech Rep, 2Faculty of Medicine, Dep of Pharmacology andCclinical 
Pharmacology, Bratislava, SlovakiaobjeCtives: Exacerbations of COPD are the 
main cause of medical visits and hospitalizations of patients with COPD and lead 
to significant increases in resource utilization and cost to the health care system. 
Prevalence of COPD in the Czech Republic is 8%. In 2010 died due to COPD 1310 men 
and 720 women. The aim of this study was to quantify the average cost of exacer-
bation of COPD and patients quality of life. Methods: We combined retrospective 
and prospective monitoring costs and quality of life in patients with different 
stages of COPD. Comparing 2 groups: patients COPD with acute exacerbations and 
group without exacerbation. Quality of life was assessed with EQ5D questionnaire. 
Involved 180 patients aged 40-89 years. Severe exacerbation was defined by COPD-
related hospitalization or death; moderate by oral or parenteral corticosteroid 
use. Results: Exacerbations in 52% solved on outpatient, 48% of patients were 
hospitalized - stage III COPD than stage II (75%vs.18%). Mean annual costs were $ 
2000 and $ 4900 for patients with two or more exacerbations. Severity of exacerba-
tions, presence of cardiovascular disease, diabetes, and long-term oxygen use were 
associated with higher adjusted costs. ConClusions: The study demonstrated 
the high cost of care and significant reduced quality of life in patients with COPD 
exacerbations compared with patients without exacerbation. Early diagnostics of 
the mild form of COPD (stage I-II), early intervention and disease management , 
